Progress in Breast Cancer
 |
| Latest Progress In Cancer Treatment 2011 |
That occur annually in the United States and 182,000 in women with breast cancer is the most common female cancer. During their lifetimes are likely to be one of the six women to breast tumor development.
Fortunately, many women with breast cancer who has a normal lifespan. Prevention, early detection and improved treatment of malignant disease and the relative freedom that occurs in the range of near-normal life are combining.
Anticancer screening technique and adjuvant therapies has contributed to the greater use of advanced breast cancer survival and mortality rates are decreasing. Preventive measures to help reduce the risk of breast cancer for at least several months, regular exercise, limiting alcohol, maintaining a healthy weight, and breast-feeding are included.
 |
| Halaven |
1. Halaven (eribulin) - approved by the FDA in November 2010, the sea-sponge - a product of the previously received an anthracycline and a taxane for the treatment of patients with metastatic breast cancer.
 |
| Faslodex |
2. Faslodex (Fulvestrant) is a selective estrogen receptor down - regulator (SERD), and disease progression in women with postmenopausal hormone receptor - positive metastatic breast cancer, FDA approval of the following antiestrogen therapy. Initially, fulvestrant approved dose of 250 mg once-monthly administration, however, FDA has recently granted on the basis of fulvestrant 500 mg monthly for most of the positive results of two studies are acknowledged.
Progression of gastric cancer
 |
| Herceptin for gastric cancer |
Progression of pancreatic cancer
Targeted therapies have shown promise in pancreatic tumors as small molecule non-biological (artificial) agents are located. It is the function of tyrosine kinases, many of these agents in a number of cellular growth factor receptors, and rapamycin (mTOR) mammalian target of target. Sunitinib and everolimus: two molecularly target agents, such as randomized trials have shown benefit.
 |
| Sutent |
 |
| Afinitor (everolimus) |
Progression of colorectal cancer
A KRAS proto - the adaptation of the most important step in the development of many cancers. KRAS / molecule, which acts on the switch, or activate growth factors involved in proliferation and malignant cell growth inhibition. Anticancer drugs are an essential amino acid and nucleotide substitution, Vectibix (panitumumab) and Erbitux (cetuximab) is a resistance, which are associated with KRAS proto - To enable the transition. The agent epidermal growth factor receptor (EGFR) target.
 |
| Erbitux (cetuximab) |
In Part II of this review, lung and prostate cancer development, additional topics, including developments in the treatment of cancer, will be addressed.